Table 2 Characteristics of the 28 studies included for analysis
From: Dementia and comorbidities in primary care: a scoping review
Category | Details | Number of Articles | |
|---|---|---|---|
Year of Publication | 2017 | 5 | |
2018 | 5 | ||
2019 | 2 | ||
2020 | 4 | ||
2021 | 7 | ||
2022 | 5 | ||
Countries Studieda | United States of America | 9 | |
United Kingdom | 4 | ||
Germany | 4 | ||
Singapore | 3 | ||
Netherlands | 3 | ||
Canada | 1 | ||
China | 1 | ||
Denmark | 1 | ||
Italy | 1 | ||
Japan | 1 | ||
Portugal | 1 | ||
Spain | 1 | ||
Taiwan | 1 | ||
Type of Study | Quantitative | Experimental | 6 |
Meta-Analysis | 1 | ||
Observational | 12 | ||
Randomized Clinical Trials | 3 | ||
Qualitative | Case Study | 1 | |
Guideline | 2 | ||
Interviews | 2 | ||
Report | 1 | ||
Type of Dementia | Dementia | 22 | |
MCI and dementia | 3 | ||
AD | 2 | ||
MCI | 1 | ||
Comorbidities Studiedb | Depression | 8 | |
Hypertension | 7 | ||
Cardiovascular | 7 | ||
General “comorbidities” | 7 | ||
Diabetes | 6 | ||
Stroke | 5 | ||
Auditory Impairment | 4 | ||
Other (e.g. dyslipidemia, osteoarticular diseases) | 2 | ||
Kidney Disease | 1 | ||
Visual Impairment | 1 | ||
Categories and Subcategories | Risk assessment and prevention | 15 | |
Screening, diagnosis, and detection | 4 | ||
Management | 9 | ||
Tools and technologies | 15 | ||
Recommendations for clinical practice | 10 | ||
Programs and initiatives | 3 | ||